[1] [2] [3] [4] [5] [6] [7] A systematic review and metanalysis of cagrisema, published in 2024, found that cagrisema may provide weight loss benefits
Effect of Dietary Pyrroloquinoline Quinone Disodium Salt on Cognitive Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema

Pros: 2% Ectoin for environmental protection can be powerful in urban or high-pollution areas Post-procedure compatible (can be applied to recovering skin) Lightweight, fast-absorbing texture Fewer total ingredients (31) than The Ordinary or INNBEAUTY - still a lot, though
Pickart, Journal Of Biomaterial Sciences Legal Status of GHK-Cu Peptide GHK-Cu is classified as a cosmetic ingredient when included in topical formulations such as serums, creams, and scalp solutions
Rapid progression also prevents accurate assessment of what concentration actually delivers results